Form 4: BridgeBio Pharma Director Andrew Lo Receives Significant Equity Grants

BridgeBio Pharma, Inc. Director Andrew Lo was granted 6,589 restricted stock units and 8,425 stock options, aligning his interests with shareholders through a multi-year vesting schedule.

Summary

• Andrew Lo, a Director at BridgeBio Pharma, Inc. (BBIO), reported the acquisition of equity securities.
• On June 20, 2025, Mr. Lo was granted 6,589 restricted stock units (RSUs) under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of BridgeBio Pharma's Common Stock.
• One-third of these RSUs will vest each year after June 20, 2025, with full vesting by June 20, 2028, contingent on Mr. Lo's continued service on the board.
• Additionally, on June 20, 2025, Mr. Lo was granted 8,425 stock options with an exercise price of $41.73 per share.
• Similar to the RSUs, one-third of the shares underlying these stock options will vest annually after June 20, 2025, achieving full vesting by June 20, 2028, also subject to his continued board service.
• The stock options have an expiration date of June 19, 2035.
• Following these transactions, Mr. Lo directly beneficially owns 54,688 shares of Common Stock and 8,425 stock options.
• He also indirectly beneficially owns 105,583 shares of Common Stock jointly with Nancy N. Lo (JTWROS).

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity grants align the director's interests with shareholders, promoting long-term commitment and value creation. This is a routine, positive corporate governance action.

Positives

• The grant of restricted stock units and stock options to Director Andrew Lo aligns his financial interests directly with the long-term performance and shareholder value of BridgeBio Pharma, Inc.
• The multi-year vesting schedule (one-third annually over three years) encourages continued commitment and service from a key board member.

Risks

• The value of the granted equity is subject to the future performance of BridgeBio Pharma's stock price, meaning the actual realized value could be lower than the current market value if the stock declines.
• Vesting of the RSUs and stock options is contingent on the reporting person's continued service on the Issuer's board of directors, posing a risk of forfeiture if service ceases prematurely.

Future Outlook

The vesting schedule for both the restricted stock units and stock options, extending to June 20, 2028, indicates an expectation of continued service by Director Andrew Lo on the BridgeBio Pharma board.

Management Comments

• The filing indicates that the grants were made under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan, reflecting a standard compensation mechanism.

Industry Context

Equity grants, such as restricted stock units and stock options, are a common form of compensation for directors and executives in the biotechnology and pharmaceutical industries. This practice is designed to align the interests of company leadership with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• The structure of these equity grants, including a multi-year vesting schedule, is consistent with typical compensation practices for non-employee directors in the U.S. biotech sector.
• While specific comparable companies are not mentioned in the filing, similar grants are observed across the industry, for example, at companies like Moderna, BioNTech, or Regeneron, where director compensation often includes a mix of cash and equity to incentivize long-term value creation.

Corporate Governance

Related Party Transactions

• The filing notes indirect beneficial ownership of 105,583 shares of Common Stock by Andrew W. Lo and Nancy N. Lo as Joint Tenants with Right of Survivorship (JTWROS), indicating a pre-existing related party holding.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with shareholder interests, potentially leading to more focused efforts on long-term stock performance.
• Employees: No direct impact on general employees is indicated by this filing, though it reflects the company's compensation philosophy for leadership.

Next Steps

• Andrew Lo's continued service on the BridgeBio Pharma board of directors is required for the vesting of the granted restricted stock units and stock options through June 20, 2028.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Form 4, Andrew Lo, Director, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Transaction, Compensation, Corporate Governance